Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Helkort is a topical antibiotic cream containing 2% fusidic acid, marketed by the Turkish company **Apeks Pharma** and manufactured by **İlko İlaç**. It is indicated for the treatment of various bacterial skin infections, such as impetigo, folliculitis, and infected dermatitis, particularly those caused by *Staphylococcus aureus*. The active ingredient, fusidic acid, works by inhibiting bacterial protein synthesis. It specifically binds to **elongation factor G (EF-G)** on the ribosome, preventing the translocation of the ribosome along the mRNA and the subsequent release of the EF-G-GDP complex, which effectively halts the elongation of the polypeptide chain. Helkort is typically supplied in 20-gram tubes for dermatological use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Helkort.